NASDAQ:ORMP Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis $2.60 +0.06 (+2.36%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.55▼$2.6150-Day Range$2.07▼$2.6852-Week Range$1.67▼$3.67Volume56,446 shsAverage Volume148,481 shsMarket Capitalization$105.64 millionP/E Ratio10.00Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Oramed Pharmaceuticals alerts: Email Address Oramed Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.82% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.03Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.01) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.03 out of 5 starsMedical Sector644th out of 936 stocksPharmaceutical Preparations Industry297th out of 436 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Oramed Pharmaceuticals.Read more about Oramed Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.82% of the outstanding shares of Oramed Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverOramed Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oramed Pharmaceuticals has recently decreased by 36.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOramed Pharmaceuticals does not currently pay a dividend.Dividend GrowthOramed Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ORMP. Previous Next 2.8 News and Social Media Coverage News SentimentOramed Pharmaceuticals has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Oramed Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 3 people have searched for ORMP on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Oramed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.70% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.73% of the stock of Oramed Pharmaceuticals is held by institutions.Read more about Oramed Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from ($0.01) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oramed Pharmaceuticals is 10.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Oramed Pharmaceuticals is 10.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 172.24.Price to Book Value per Share RatioOramed Pharmaceuticals has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Oramed Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Read More ORMP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORMP Stock News HeadlinesJuly 25 at 4:17 AM | americanbankingnews.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Below 200 Day Moving Average of $2.58July 17, 2024 | americanbankingnews.comOramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below 200-Day Moving Average of $2.58July 27, 2024 | True Market Insiders (Ad)Amazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…July 8, 2024 | investorplace.com3 Micro-Cap Moonshots for Fearless InvestorsJune 26, 2024 | prnewswire.comOramed Letter to ShareholdersJune 26, 2024 | prnewswire.comOramed Pharmaceuticals Inc. Announces the Buy-Back of its Common StockMay 29, 2024 | finance.yahoo.comORMP: Moving Oral Delivery Platform Forward, + Potential to Generate RoyaltiesMay 12, 2024 | finance.yahoo.comOramed Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)July 27, 2024 | True Market Insiders (Ad)Amazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…May 10, 2024 | investorplace.comORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q1 2024March 16, 2024 | finance.yahoo.comORMP Apr 2024 2.500 putMarch 9, 2024 | finance.yahoo.comOramed Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsFebruary 21, 2024 | msn.comOramed to reinitiate pivotal type 2 diabetes trial after Phase III flopFebruary 20, 2024 | finanznachrichten.deOramed Pharmaceuticals Inc.: Oramed Letter to ShareholdersFebruary 20, 2024 | prnewswire.comOramed Letter to ShareholdersJanuary 24, 2024 | finance.yahoo.comORMP: Multiple Potential Applications for Proprietary Oral Protein Delivery PlatformNovember 28, 2023 | msn.comOramed Pharmaceuticals (ORMP) Price Target Increased by 36.51% to 4.39November 2, 2023 | msn.comOramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21See More Headlines Receive ORMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORMP CUSIPN/A CIK1176309 Webwww.oramed.com Phone(844) 967-2633Fax972-2566-0004Employees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.26 Trailing P/E Ratio10.00 Forward P/E RatioN/A P/E GrowthN/ANet Income$5.53 million Net MarginsN/A Pretax Margin1,518.25% Return on Equity-3.83% Return on Assets-2.96% Debt Debt-to-Equity RatioN/A Current Ratio5.28 Quick Ratio5.28 Sales & Book Value Annual Sales$1.34 million Price / Sales78.83 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.64Miscellaneous Outstanding Shares40,630,000Free Float35,063,000Market Cap$105.64 million OptionableOptionable Beta1.79 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Nadav Kidron Esq. (Age 50)President, CEO & Executive Chairman Comp: $754.3kMr. David Silberman CPA (Age 40)CFO & Treasurer Comp: $259.53kDr. Miriam Kidron Ph.D. (Age 84)Chief Scientific Officer & Director Comp: $503.95kMr. Joshua Hexter (Age 54)Chief Operating & Business Officer Comp: $326.94kKey CompetitorsEntasis TherapeuticsNASDAQ:ETTXStealth BioTherapeuticsNASDAQ:MITOAlto NeuroscienceNYSE:ANROPrecigenNASDAQ:PGENLyell ImmunopharmaNASDAQ:LYELView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 23,165 shares on 5/20/2024Ownership: 0.057%Murchinson Ltd.Bought 329,495 shares on 5/16/2024Ownership: 3.395%View All Institutional Transactions ORMP Stock Analysis - Frequently Asked Questions How have ORMP shares performed this year? Oramed Pharmaceuticals' stock was trading at $2.31 on January 1st, 2024. Since then, ORMP stock has increased by 12.6% and is now trading at $2.60. View the best growth stocks for 2024 here. How were Oramed Pharmaceuticals' earnings last quarter? Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) posted its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.02 by $0.02. Who are Oramed Pharmaceuticals' major shareholders? Top institutional investors of Oramed Pharmaceuticals include Concourse Financial Group Securities Inc.. Insiders that own company stock include Michael Rabinowitz, Nadav Kidron, Yadin Rozov and Kevin Rakin. View institutional ownership trends. How do I buy shares of Oramed Pharmaceuticals? Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Oramed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and DURECT (DRRX). This page (NASDAQ:ORMP) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORMP Stock Alerts